Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111319
Status:
COMPLETED
Last Update Posted:
2009-03-26
First Post:
2005-05-19
Brief Title:
VELCADEMelphalanPrednisone Versus MelphalanPrednisone in Patients With Previously Untreated Multiple Myeloma
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
An Open-Label Randomized Study of VELCADEMelphalanPrednisone Versus MelphalanPrednisone in Subjects With Previously Untreated Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary reason for this study is to determine whether the addition of VELCADE bortezomib for injection to standard melphalanprednisone MP therapy improves the time to disease progression TTP in subjects with previously untreated multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None